Colibactin: A Double-Edged Sword for Human Health

Understanding the pks island and colibactin connection

The pks island is a 54-kilobase DNA segment that encodes large enzymes responsible for assembling complex molecules called polyketides.^1,2 These molecules serve various roles in nature, including acting as antibiotics and toxins. In Escherichia coli, the pks island enables the synthesis of colibactin, a molecule that induces DNA damage in host cells. Discovered in 2006, colibactin was linked to DNA damage in mammalian cells infected by E. coli strains carrying the pks island.^3,4

The pks island is not exclusive to pathogenic bacteria; it is also found in commensal gut residents and probiotics like E. coli Nissle 1917, which is used to treat gut disorders. Beyond E. coli, the pks island appears in bacteria associated with olive trees, bees, and marine sponges, highlighting its evolutionary significance for microbial adaptation across diverse hosts.⁵

How colibactin contributes to DNA damage, mutational signatures, and CRC

The harmful edge of colibactin’s double-edged sword shines brightest in cancer research. At its core, colibactin is a genotoxin: it cross-links DNA strands, causing double-strand breaks that cells struggle to repair.^1,3,5-8 This leads to mutations, and over time, those glitches can spark tumors. Consistent with this mechanism, studies show that bacteria harboring pks islands are enriched in the guts of CRC patients—up to 60% in some cohorts, compared with 20% in healthy people.^9-12 In mouse models, these bacteria promote inflammation and tumor growth, especially when combined with a disrupted microbiome or inflammatory bowel disease.¹³

At the genomic level, an analysis of over 2,000 CRC genomes spanning five continents by the Mutographs project uncovered “mutational signatures” like SBS88 and ID18—distinct DNA scars attributable to colibactin.^10,12,14-16 These signatures are more common in high-incidence countries like Japan and in individuals with early-onset CRC, which has doubled globally in young adults under 50. Even more concerning, these signatures appear in normal colon cells by age 10, suggesting that early-life exposure imprints a “head start” for cancer decades later.

This raises a critical question: why is there a surge in CRC among young adults? The western diet seems to alter the composition of the microbiota, whereby E. coli phylogroups harboring pks islands are disproportionately overrepresented.^17-18 Compounding this effect, antibiotics or prebiotics, such as inulin, can increase colibactin production. Environmental exposures also play a role: food contaminants, such as the mycotoxin deoxynivalenol, increase the genotoxicity of enterobacteria harboring the pks island.¹⁸

Beyond the gut, strains with pks islands cause urinary tract infections and sepsis, damaging bladder cells and potentially contributing to prostate or bladder cancers. In newborns, early colonization can breach gut barriers, leading to immune issues or chronic inflammation—collateral damage from the bacteria’s survival tactics.

The dual nature of colibactin as both a microbial survival tool and a cancer-linked genotoxin

The story doesn’t end with DNA damage. Recent research suggests that colibactin and other polyketides play complex roles in the gut ecosystem, helping bacteria compete with their neighbors and shaping the microbiome’s composition. Some studies even hint at immune-modulating properties, where colibactin could influence inflammation or fine-tune the body’s response to infections.^{1,2,4-6,12,19-21} This double-edged nature makes colibactin and other pks island–encoded polyketides both a threat and an opportunity, highlighting the versatility of these metabolites.⁵ Understanding how colibactin works could unlock strategies to prevent cancer or harness its beneficial effects while minimizing harm. 

More broadly, this functional flexibility is rooted in the pks island itself, which provides bacteria with a competitive advantage, enabling them to produce diverse molecules that address various challenges, such as fighting off rival microbes, surviving hostile environments, and interacting with hosts. In a balanced microbiome, the pks island can protect against pathogens. However, in the human host, its impact depends on context: early exposure may increase inflammation, leading to cancer risk. The OncoKB database highlights mutations driven by these processes, offering insights for potential therapeutic development, such as harnessing colibactin’s antimicrobial properties.¹⁶

The pks island evolved to enhance bacterial fitness. Producing colibactin is energy-intensive but conserved across species because of its selective benefits. It acts as a weapon in microbial competition, damaging the DNA of rival bacteria and inducing prophages that eliminate competitors like Vibrio cholerae, helping pks⁺ strains dominate the gut and promote colonization. For bacteria, it’s an adaptive toolkit regulated by environmental factors like oxygen, iron, and sugar. Additionally, byproducts such as C12-Asn-GABA act as natural painkillers,⁵ while C14-Asn displays antibiotic activity against multidrug-resistant Staphylococcus aureus.²² The cluster also collaborates with other pathways to produce siderophores and microcins, supporting bacterial survival in iron-poor or inflamed environments.⁵

For health, prevention strategies might focus on reducing early exposure through microbiome-friendly diets or vaccines. Drugs like mesalamine suppress colibactin production, with potential anti-cancer effects.² However, eliminating pks⁺ bacteria entirely could disrupt gut balance, as they’ve coexisted with humans for millennia. Ongoing research, including global biosample studies, will further clarify these patterns.

Ultimately, the pks island illustrates that our microbiomes can be both allies and adversaries. Colibactin’s story is an evolutionary trade-off—sometimes harming human health but often benefiting it. As CRC rates rise in younger populations, understanding this balance is crucial for developing effective defenses.

How ATCC supports pks research for therapeutic innovation

ATCC is a global nonprofit that provides authenticated biological materials to researchers worldwide. It offers a wide range of cell lines, microbial strains—both with and without pks islands—and tools for controlled experiments, genetic comparisons, and studying colibactin’s effects on human cells. 

Key bacterial strains for studying pks islands and colibactin biology

ATCC provides several strains known to harbor the pks island (Table 1). These strains are essential for dissecting how the PKS enzymes assemble colibactin and its metabolites, which can damage DNA but also confer antimicrobial or pain-relieving properties. The best-known is E. coli Seattle 1946 (ATCC® 25922™), which has been widely used both for the complex molecules produced by its pks island and as a model organism in colibactin research—for example, to investigate how environmental factors such as copper, L-tryptophan, or antibiotics (e.g., polymyxin B) modulate colibactin production and genotoxicity.²³ Studies have shown that this strain helps reveal interactions that reduce colibactin’s harmful effects, potentially guiding anti-cancer strategies.²³ It’s also a standard for antibiotic susceptibility testing, bridging microbiology and drug development.^24-26

Essential tools and resources for colibactin research and therapeutic development 

This research line has huge potential for therapies, and ATCC goes beyond microbial strains, accelerating it by providing additional tools: 

Cell lines for genotoxicity assays and beyond: ATCC provides the most commonly used human epithelial cell lines derived from CRCs (e.g.,  HCT-116, Caco-2, HT-29) and normal health tissues (e.g., HIEC-6, CCD 841 CoN, FHC). Those well-characterized cell lines and colon 3-D tumor organoid models can be used to test colibactin’s DNA-damaging effects.^{5,6,11,20,27-30} Researchers infect these cell lines with pks⁺ strains to measure mutational signatures (such as SBS88 and ID18 from the Mutographs project) and link them to cancer hallmarks. This has revealed how colibactin induces double-strand breaks, prophage activation in rivals, or even microbiome remodeling.  

Genomic and molecular resources: ATCC’s bioinformatics tools and sequenced genomes (e.g., via the ATCC Genome Portal) help map pks cluster evolution across bacteria. This supports comparative studies showing the pks island in gut, urinary, or sepsis isolates, aiding the identification of therapeutic targets such as the ClbP enzyme (which activates colibactin) and ClbS (which detoxifies it).^31,32

Metagenomic analytical reference materials: Through mock or synthetic microbial communities and DNA controls, ATCC ensures reproducible and accurate metagenomic research, crucial for identifying and monitoring the gut microbiome changes. 

Antimicrobial applications: ATCC’s antimicrobial-resistant strain collection helps screen the PKS byproducts like C14-Asn against superbugs, addressing antibiotic resistance—a global health crisis. 

ATCC plays a pivotal role in advancing therapeutic research by providing essential, standardized microbial strains and tools. These resources enable precise experiments on colibactin’s biosynthesis and host interactions. Standardized isolates from ATCC reduce variability from strain drift, ensuring consistent, reproducible results.

By emphasizing quality and reliability, ATCC supports drug screening and microbiome studies, helping researchers develop therapies that target colibactin production or harness its beneficial effects. Access to a wide range of bacterial strains and molecular tools bridges basic scientific discoveries with practical therapeutic applications.

The future: Turning threats into opportunities

The story of the pks island and colibactin is still unfolding. As scientists learn more about how this gene cluster and its products impact human health, new possibilities emerge. Could we develop probiotics that outcompete colibactin-producing bacteria? Might there be ways to neutralize the genotoxic effects of colibactin before it causes harm? Or could polyketides inspire next-generation drugs that fight cancer or other diseases?

What’s clear is that the pks island is much more than a genetic curiosity. It’s a testament to the power and complexity of microbial life—and a reminder that what’s dangerous in one context may be beneficial in another. With ATCC resources supporting the research community, we’re better equipped than ever to explore these questions and translate discoveries into therapies that improve human health. As research continues, we may find that the key to harnessing the “Swiss army knife” of bacteria lies not in fear, but in curiosity and collaboration.

Table 1: ATCC strains that harbor the pks island for colibactin synthesis. A search of the ATCC Genome Portal for strains that possess clbB, based on NCBI reference OM103704.1, was conducted to determine whether colibactin genes were present.

Did you know?

There are over 6,500 microbial genomes available on the ATCC Genome Portal.

Learn more

References

1. Wilson MR, Jiang Y, Villalta PW, et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science 363(6428): eaar7785, 2019. PubMed: 30765538
2. Addington E, Sandalli S, Roe AJ. Current understandings of colibactin regulation. Microbiology (Reading) 170(2): 001427, 2024. PubMed: 38314762
3. Nougayrède JP, Homburg S, Taieb F, et al. Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells. Science 313(5788): 848-851, 2006. PubMed: 16902142
4. Faïs T, Delmas J, Barnich N, Bonnet R, Dalmasso G. Colibactin: More Than a New Bacterial Toxin. Toxins (Basel) 10(4): 151, 2018. PubMed: 29642622
5. Chagneau CV, Payros D, Tang-Fichaux M, Auvray F, Nougayrède JP, Oswald E. The pks island: a bacterial Swiss army knife? Colibactin: beyond DNA damage and cancer. Trends Microbiol 30(12): 1146-1159, 2022. PubMed: 35672224
6. Sadecki PW, Balboa SJ, Lopez LR, Kedziora KM, Arthur JC, Hicks LM. Evolution of Polymyxin Resistance Regulates Colibactin Production in Escherichia coli. ACS Chem Biol 16(7): 1243-1254, 2021. PubMed: 34232632
7. Kaewkod T, Tobe R, Tragoolpua Y, Mihara H. Medicinal plant extracts protect epithelial cells from infection and DNA damage caused by colibactin‐producing Escherichia coli , and inhibit the growth of bacteria. J Appl Microbiol 130(3): 769-785, 2021. PubMed: 32767847
8. Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci 107(25): 11537-11542, 2010. PubMed: 20534522
9. Miyasaka T, Yamada T, Uehara K, et al. Pks ‐positive Escherichia coli in tumor tissue and surrounding normal mucosal tissue of colorectal cancer patients. Cancer Sci 115(4): 1184-1195, 2024. PubMed: 38297479
10. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks⁺ E. coli. Nature 580(7802): 269-273, 2020. PubMed: 32106218
11. Buc E, Dubois D, Sauvanet P, et al. High Prevalence of Mucosa-Associated E. coli Producing Cyclomodulin and Genotoxin in Colon Cancer. PLoS One 8(2): e56964, 2013. PubMed; 23457644
12. Terlouw D, Boot A, Ducarmon QR, et al. Enrichment of colibactin-associated mutational signatures in unexplained colorectal polyposis patients. BMC Cancer 24(1): 104, 2024. PubMed: 38238650
13. Arthur JC, Perez-Chanona E, Mühlbauer M, et al. Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota. Science 338(6103): 120-123, 2012. PubMed: 22903521
14. Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks⁺ E. coli. Nature 580(7802): 269-273, 2020. PubMed: 32106218
15. Arthur JC. Microbiota and colorectal cancer: colibactin makes its mark. Nat Rev Gastroenterol Hepatol 17(6): 317-318, 2020. PubMed: 32317778
16. Díaz-Gay M, Dos Santos W, Moody S, et al. Geographic and age variations in mutational processes in colorectal cancer. Nature 643(8070): 230-240, 2025. PubMed: 40267983
17. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat Rev Microbiol 8(3): 207-217, 2010. PubMed: 20157339
18. Payros D, Dobrindt U, Martin P, et al. The Food Contaminant Deoxynivalenol Exacerbates the Genotoxicity of Gut Microbiota. mBio 8(2): e00007-17, 2017. PubMed: 28292979
19. Jans M, Vereecke L. Physiological drivers of pks⁺ E. coli in colorectal cancer. Trends Microbiol 33(9): 1003-1017, 2025. PubMed: 40335416
20. Teppabut W, Tragoolpua Y, Kaewkod T. Antimicrobial and Cytoprotective Effects of Tea Extracts Against Escherichia coli-Producing Colibactin Toxin Infections. Antibiotics (Basel) 14(9): 886, 2025. PubMed: 41009865
21. Ullah S, Wu C, Zou X, et al. Understanding microbiota-driven oncogenesis: The role of metabolites in tumorigenesis. iScience 28(12): 113945, 2025. PubMed: 41333317
22. Faïs T, Cougnoux A, Dalmasso G, Laurent F, Delmas J, Bonnet R. Antibiotic Activity of Escherichia coli against Multiresistant Staphylococcus aureus. Antimicrob Agents Chemother 60(11): 6986-6988, 2016. PubMed: 27600034
23. Bayne C, Boutard M, Zaplana T, Tolonen AC. L-tryptophan and copper interactions linked to reduced colibactin genotoxicity in pks⁺ Escherichia coli. mSystems 9(10): e00992-24, 2024. PubMed: 39264195
24. Miller RA, Walker RD, Baya A, et al. Antimicrobial Susceptibility Testing of Aquatic Bacteria: Quality Control Disk Diffusion Ranges for Escherichia coli ATCC 25922 and Aeromonas salmonicida subsp. salmonicida ATCC 33658 at 22 and 28°C. J Clin Microbiol 41(9): 4318-4323, 2003. PubMed: 12958263
25. Sjölund M, Bengtsson S, Bonnedahl J, Hernandez J, Olsen B, Kahlmeter G. Antimicrobial susceptibility in Escherichia coli of human and avian origin—a comparison of wild-type distributions. Clin Microbiol Infect 15(5):461-465, 2009. PubMed: 19260874
26. Tzimotoudis N, Mataragka A, Andritsos ND, Ikonomopoulos J. Antibiotic Susceptibility Testing of Escherichia coli and Coliform Isolates Detected in Samples of Drinking Water from Central Greece. Appl Sci 15(5): 2664, 2025.
27. McCoy CS, Mannion AJ, Feng Y, et al. Cytotoxic Escherichia coli strains encoding colibactin, cytotoxic necrotizing factor, and cytolethal distending toxin colonize laboratory common marmosets (Callithrix jacchus). Sci Rep 11(1): 2309, 2021. PubMed: 33504843
28. Secher T, Samba-Louaka A, Oswald E, Nougayrède JP. Escherichia coli Producing Colibactin Triggers Premature and Transmissible Senescence in Mammalian Cells. PLoS One 8(10): e77157, 2013. PubMed: 24116215
29. Mirzarazi M, Bashiri S, Hashemi A, Vahidi M, Kazemi B, Bandehpour M. The OmpA of commensal Escherichia coli of CRC patients affects apoptosis of the HCT116 colon cancer cell line. BMC Microbiol 22(1): 139, 2022. PubMed: 35590263
30. Iyadorai T, Mariappan V, Vellasamy KM, et al. Prevalence and association of pks⁺ Escherichia coli with colorectal cancer in patients at the University Malaya Medical Centre, Malaysia. PLoS One 15(1): e0228217, 2020. PubMed: 31990962
31. Benton B, King S, Greenfield SR, et al. The ATCC Genome Portal: Microbial Genome Reference Standards with Data Provenance. Microbiol Resour Announc 10(47): e00818-21, 2021. PubMed: 34817215
32. Volpe MR, Velilla JA, Daniel-Ivad M, et al. A small molecule inhibitor prevents gut bacterial genotoxin production. Nat Chem Biol 19(2): 159-167, 2023. PubMed: 36253549